AstraZeneca licenses respiratory drug to Insmed

AstraZeneca licenses respiratory drug to Insmed
 

Drugmaker Insmed Inc (INSM.O) said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc (AZN.L) in a deal worth $150 million (117.9 million pounds).
AstraZeneca will get $30 million in upfront fees and $120 million in various milestone payments, Insmed said.
The deal adds AstraZeneca's AZD7986 compound to Insmed's pipeline. AZD7986 is designed to stop an enzyme that regulates inflammation in the respiratory system.
Insmed, which focuses on developing treatments for respiratory diseases, said it would start a mid-stage study... read more

 
5 October 2016 in Business, Views: 38
Source: Reuters
Share:
  •  





    News Widget for Webmasters



    Bring Eugene's son back home immediately

    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31